Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Evaluating the therapeutic potential of L-arginine and licorice extract in letrozole-induced polycystic ovary syndrome in rats: targeting interconnected molecular pathways.

Created on 25 Aug 2026

Authors

Yasmeen El-Sayed, Heba A El-Ghaweet, Abdelaziz A Elrefaeey, Amoura M Abou-El-Naga

Published in

Scientific reports. Volume 16. Issue 1. Aug 24, 2026. Epub Aug 24, 2026.

Abstract

Polycystic Ovary Syndrome (PCOS) is a common disorder characterized by hyperandrogenism and ovarian dysfunction. L-arginine and licorice extract, known for their antioxidant properties, are used to manage infertility. This study aimed to evaluate the effects of licorice extract and L-arginine on ovarian morphology, oocyte maturation, and pregnancy rates in PCOS-induced rats. Female rats were randomly assigned into six groups (n = 12): Group I (Control) received no treatment; Group II (Licorice) received 150 mg/kg licorice extract for 21 days; Group III (L-Arginine) received 22.9 mg/kg L-arginine for 21 days; Group IV (PCOS Model) received 1 mg/kg letrozole for 21 days to induce PCOS; Group V (Licorice + PCOS) received 150 mg/kg licorice extract post-PCOS induction; Group VI (L-Arginine + PCOS) received 22.9 mg/kg L-arginine post-PCOS induction. The study analyzed ovarian morphology, serum lipid profiles, antioxidant markers, nitric oxide levels, inflammatory cytokines, reproductive hormones, and Amhr2 gene expression, in conjunction with ovarian histopathology and immunohistochemistry for PCNA and Ki-67. L-arginine and licorice extract significantly improved lipid profiles, reduced oxidative stress (MDA, NO), and enhanced antioxidant activity (SOD, Catalase). They also showed beneficial effects on ovarian function, inflammation, and reproductive hormones, suggesting their therapeutic potential in managing PCOS. Fertility success improved from 33.3% in PCOS rats to 100% in both treatment groups, with increased litter sizes (9.25 ± 0.63 and 8.25 ± 0.75, respectively).

PMID:
42637851
Bibliographic data and abstract were imported from PubMed on 25 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement